Symphogen is leading the development of antibody mixture therapeutics to improve the treatment of cancer.

Symphogen's growing pipeline of cancer programs reflects a new approach to fighting cancer with unique mechanisms based on multiple simultaneous attacks on tumors. The result is improved efficacy and the potential to reduce the development of drug resistance.

mAb Mixtures and Cancer